About the LIFT-AD Trial

The LIFT-AD Trial is evaluating the safety and effectiveness of an investigational medication (a medication not approved for routine clinical use) for people with mild to moderate Alzheimer’s disease.

The trial involves 9 clinic visits over the course of up to 30 weeks. There is no cost to participate in this study. All study medication and office visits are included at no cost to participants.

Participants are randomly assigned to a treatment group. They receive either the investigational medication or a placebo (a substance that looks like the investigational medication but contains no active ingredients), which is administered through a subcutaneous injection (a small injection under the skin) at home using provided prefilled syringes.

The trial will consist of up to 4 weeks of screening, followed by 26 weeks of trial treatment, and a 4-week safety follow-up period. During the treatment period, the support person or caregiver must be available to supervise the daily administration of the investigational medication.

After completing the LIFT-AD Trial, participants will have the option to join a longer-term open-label extension, which allows all participants to receive the investigational medication.

Alzheimer’s disease can be debilitating and have a negative impact on daily life. We need clinical research to find safe and effective treatments.